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Abstract  
Platelet concentrate (PC) transfusions are a life-saving adjunct to control and prevent 
bleeding in cancer, haematological, surgical and trauma patients. PC availability and 
safety are limited by the development of platelet storage lesions (PSLs) and risk of 
bacterial contamination. PSLs are a series of biochemical, structural and functional 
changes that occur from blood collection to transfusion. Understanding of PSLs is key 
for devising interventions that prolong PC shelf life to improve PC access and 
wastage. This paper will review advancements in clinical and mechanistic PSL 
research. 
 
In brief, exposure to artificial surfaces and high centrifugation forces during PC 
preparation initiate PSLs by causing platelet activation, fragmentation and 
biochemical release. During room temperature storage, enhanced glycolysis and 
reduced mitochondrial function leads to glucose depletion, lactate accumulation and 
product acidification. Impaired adenosine triphosphate generation reduces platelet 
capacity to perform energetically demanding processes such as hypotonic stress 
responses and activation/aggregation. Storage-induced alterations in platelet surface 
proteins such as thrombin receptors and glycoproteins decrease platelet aggregation. 
During storage, there is an accumulation of immunoactive proteins such as leucocyte-
derive cytokines (tumour necrosis factor α (TNF-α), interleukin (IL)-1α, IL-6, IL-8) 
and soluble CD40 ligand (sCD40L) which can participate in transfusion-related acute 
lung injury and non-haemolytic transfusion reactions. Storage-induced microparticles 
have been linked to enhanced platelet aggregation and immune system modulation.  
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Clinically, stored PCs have been correlated to reduced corrected count increment, 
post-transfusion platelet recovery and survival across multiple meta-analyses. Fresh 
PC transfusions have been associated with superior platelet function in vivo, however 
these differences were abrogated after a period of circulation. There is currently 
insufficient evidence to discern the effect of PSLs on transfusion safety. 
 
Various bag and storage media changes have been proposed to reduce glycolysis and 
platelet activation during room temperature storage. Moreover, cryopreservation and 
cold storage have been proposed as potential methods to prolong PC shelf life by 
reducing platelet metabolism and bacterial proliferation. However, further work is 
required to elucidate and manage the PSLs specific to these storage protocols prior to 
its implementation in blood banks.  
 
Keywords: 
Platelets, platelet storage lesions, storage, age, transfusion, microparticles, transfusion 
reaction, cold-storage. 
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Abbreviations 
5-HT=serotonin, ABLE=Age of Blood Evaluation, APC=activated protein C, 
ADP=adenosine diphosphate, ATP=adenosine triphosphate, BC=buffy coat, 
BTHC=n-Butyryl tri-n-hexyl citrate, CCI=corrected count increment, CD=cluster of 
differentiation, CD40L=CD40 ligand, CD62P=P-selectin, cGMP=cyclic guanine 
monophosphate, CI=confidence interval, DINCH=1,2-cyclohexane-dicarboxylic acid 
diisonoylester, DMSO=dimethyl sulfoxide, FDA= Food and Drug Administration, 
FVa=activated factor V, GP=glycoprotein, HSR=hypotonic stress responses, 
IL=interleukin, LPS=lipopolysaccharide, MCP-1=monocyte chemoattractant protein-
1, NHTR=non-haemolytic transfusion reaction, NO=nitric oxide,  PAR=protease-
activated receptors, PAS=platelet additive solution, PC=platelet concentrate, 
PMPs=platelet microparticles, PRP=platelet rich plasma, PRT=pathogen reduction 
technologies, PS=phosphatidylserine, PSL=platelet storage PVC= plasticised 
polyvinyl chloride, ROTEM=rotational thromboelastometry, TCA=tricarboxylic acid, 
TEG=thromboelastography, TEHTM=tri-(ethylhexyl)-trimellitate, TNF-α=tumour 
necrosis factor α, TRALI=transfusion-related acute lung injury, TRANSFUSE= 
Standard Issue Transfusion versus Fresher Red Blood Cell Use in Intensive Care, 
TRIM=transfusion-related immunomodulation, USA=United States of America, 
VASP=vasodilator-stimulated phosphoprotein , vWF=von Willebrand factor  
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Introduction 
Platelets are discoid, anucleate, cellular fragments that originate primarily from 
marrow megakaryocytes [1]. They circulate in the bloodstream for 8-10 days, after 
which they are cleared by macrophages. This occurs in the liver and spleen via 
recognition of absent, antibody-coated or desialylated surface glycoproteins (GP) [2-
4]. 
 
Platelets play major roles in haemostasis, inflammation and wound healing [5].  
Platelet adhesion to the subendothelial matrix in a damaged vessel is the initial step in 
primary haemostasis (Figure 1) [5]. Subsequently, platelets activate in the presence of 
biochemical agonists such as thrombin, adenosine diphosphate (ADP), thromboxane, 
epinephrine and serotonin (5-HT) [5].  Activated platelets then change shape to form 
extensive pseudopodia [5]. Dense and α granules fuse with the platelet plasma 
membrane via exocytosis to release granule contents [5].  ADP and 5-HT in dense 
granules amplify activation of surrounding platelets. α granules contain large adhesive 
proteins, mitogenic factors, coagulation factors and protease inhibitors that participate 
in platelet aggregation and coagulation (Table 1) [5]. P-selectin (CD62P) which 
resides in the α granule membrane at rest becomes exposed on the platelet plasma 
membrane, and plays key roles in platelet-leucocyte interactions.  
 
Surface glycoproteins, GPIIb/IIIa and GPIb/V/IX complex on activated platelets 
interact with fibrinogen and von Willebrand factor (vWF) for platelet aggregation [5]. 
This process forms the haemostatic plug, signifying the end of primary haemostasis. 
Secondary haemostasis occurs when sufficient platelet activation initiates the 
coagulation cascade to generate thrombin and form a stable platelet-fibrin clot [5].  
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Platelet concentrate (PC) transfusions are a life-saving adjunct for the control and 
prevention of severe bleeding (Table 2). PC availability and safety are limited by the 
development of platelet storage lesions (PSLs) and risk of bacterial contamination. 
PSLs are the sum of biochemical and functional changes that occur in PCs from blood 
collection to transfusion. This paper will review advancements in clinical and 
mechanistic PSL research.  
 
PC preparation and storage protocols 
Platelets are purified from whole blood via centrifugation which separates blood 
components based on density. The three types of PC products— platelet rich plasma 
(PRP) PCs, buffy coat (BC) PCs and apheresis PCs; differ in the sequence of 
centrifugation steps [6] (Figure 2), described in detail by Greening et al. [6] and 
reviewed by Vassallo et al. [7]).  Purified platelets are resuspended in plasma, platelet 
additive solution (PAS) or a mixture of both (reviewed in detail by Gulliksson [8]  
and Van der Meer [9]). Prior to storage, PCs are filtered based on size and charge to 
minimise contaminating proteins and leucocytes (United States of America (USA): 
<5x10
6 
leucocytes/PC, other countries: <1x10
6 
leucocytes/PC) [6]. In some 
jurisdictions, PCs undergo pathogen reduction technologies (PRTs) which inactivate 
viral and bacterial nucleic acid [10]. This prevents bacterial proliferation during 
storage and renders viruses ineffective thereby prolonging shelf life and preventing 
transfusion-induced infections.   
 
Post-preparation, PCs are stored at 20-24°C under constant horizontal agitation in n-
Butyryl tri-n-hexyl citrate (BTHC) or tri-(ethylhexyl)-trimellitate (TEHTM) 
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plasticised polyvinyl chloride (PVC) bags (reviewed in detail by Van der Meer and 
Korte [11]).  PC shelf life is 3 days in Japan, 4 days in Germany, 5 days in Australia 
and USA and 7 days in the United Kingdom, Netherlands and Canada (see 
Supplementary Table 1 for jurisdictional differences) [12].   
 
Mechanisms of PSL 
PSLs occur due to platelet metabolism in the setting of in vitro preparation and 
storage pressures. These changes ultimately lead to disturbances in platelet activation, 
aggregation, coagulation and immune functions (Figure 3). 
 
Pre-storage platelet activation 
Platelet exposure to artificial surfaces and high centrifugation forces during PC 
preparation induce cellular activation, fragmentation and biochemical release [7, 13].  
The extent of platelet activation varies between preparation methods. PRP PCs exhibit 
increased platelet activation markers (CD62P exposure, GPIIb/IIIa activation, loss of 
GPIb, platelet factor 4 (PF4) activity) compared to apheresis PCs as platelets are 
pelleted against the surface of the container during hard centrifugation [7]. In contrast, 
BC platelets are protected from the surface of the container by the red blood cell 
pellet during hard centrifugation resulting in the least centrifugation-induced 
activation [6]. Similar to its effects on pathogen nucleic acids, PRTs can inactivate 
platelet RNA to induce platelet activation [14]. Platelets from PRT-treated PCs were 
less responsive to collagen, ADP and thrombin-receptor activating peptide stimulation 
in vitro [15].  
 
Storage-induced platelet activation 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 8 
During storage, platelet-container interactions, room temperature environment and 
agitation are associated with platelet lysis and activation [11, 16, 17]. This is reflected 
by the progressive accumulation of lactate dehydrogenase, α granule (vWF, platelet 
derived growth factor) and dense granule (5-HT) contents in the storage media along 
with enhanced exposure of CD62P and phosphatidylserine (PS) over 5 days of storage 
[18-20]. While activated PCs may have improved haemostatic effects, increased 
CD62P exposure and GPIbα shedding are associated with decreased post-transfusion 
platelet survival [4, 21].   
 
Alterations in ATP generation 
Platelets are metabolically active and primarily rely on the hydrolysis of adenosine 
triphosphate (ATP) to drive the chemical reactions required for function and survival 
[22].  ATP is generated via two key pathways in platelets with 85% of ATP produced 
via the tricarboxylic acid (TCA) cycle (Figure 4) [23].  It follows that PC media 
undergo glucose depletion, lactate accumulation and acidification secondary to 
glycolysis with finite nutrients and absent clearance mechanisms [24]. Metabolomics 
analysis with ultra performance liquid chromatography demonstrated that glucose is 
exclusively converted to lactate via glycolysis, with decreased mitochondrial function 
secondary to TCA inhibition during the first 3 days of in vitro storage [25].  Towards, 
the end of shelf life, oxidative phosphorylation increases to generate ATP when 
substrates for glycolysis become depleted [25]. In spite of this, platelets from stored 
PCs exhibit inferior hypotonic stress responses (HSR) demonstrating a reduced 
capacity to perform energetically demanding processes [26].  HSR is associated with 
platelet survival in vivo and corroborates the finding that mitochondrial function is 
critical for platelet aggregation and survival [26, 27]. Importantly, mitochondrial 
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protection via acetyl-L-carnitine and ascorbic acid fail to improve platelet function 
suggesting that downstream non-bioenergetic processes are also impaired during 
storage [28].  
 
Platelet surface receptor modifications 
Storage-induced alterations in platelet surface proteins and metabolism lead to 
decreased platelet aggregation in response to thrombin, collagen, platelet activating 
factor, epinephrine and ADP [29-31]. Early studies found that storage-induced 
decreases in thrombin sensitivity were linked to reduced high affinity thrombin 
binding sites [32].  Thrombin binds G-protein-coupled protease-activated receptors 1 
and 4 (PAR1, PAR4) to induce platelet secretion and aggregation. Both PAR1 and 
PAR4 expression decreased over 5 days of storage, impairing PAR4-mediated but not 
PAR1-mediated platelet aggregation [33].  Additionally, GPIbα shedding during PC 
storage is associated with decreased platelet aggregation [4]. The transfusion of stored 
PCs with 5G6 fragment, which blocks GPIbα shedding, shortened bleeding time in 
GPIbα-deficient mice [4]. Notably, GPIbα shedding is not universal across 
preparation methods as mean surface GPIbα expression remains stable until day 9 in 
BC PCs [34].  
 
Nitric oxide pathway 
PC storage also impairs platelet aggregation by enhancing multiple steps of the nitric 
oxide/cyclic nucleotide-dependent inhibitory pathway [35, 36].  Nitric oxide (NO) is a 
potent vasodilator and platelet inhibitor released by endothelial cells to maintain the 
balance of haemostasis. NO stimulation leads to intracellular cyclic guanine 
monophosphate (cGMP) accumulation which drives protein kinase G phosphorylation 
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of vasodilator-stimulated phosphoprotein (VASP). Phosphorylated VASP retains 
GPIIb/GPIIIa in resting conformation thereby inhibiting fibrinogen binding, adhesion 
and aggregation. Platelets in 5 day old PCs become sensitised to NO with stronger 
cGMP accumulation after NO donor stimulation [35]. Furthermore, basal cGMP 
concentration and VASP-phosphorylation rises by four to five times and 1.5 times 
respectively over 5 days of in vitro storage [36].  This leads to inhibited thrombin 
receptor activator-peptide-6 and collagen induced platelet aggregation in five day old 
PCs [35].  
 
Thrombotic PMPs 
PMPs are submicron membrane-bound vesicles that are shed during platelet 
activation, stress and integrin-mediated destabilisation of the actin cytoskeleton [37, 
38]. PCs accumulate approximately 5000 PMPs/µl after 5 days of storage [39, 40].  
Preparation- and storage-induced platelet microparticles (PMPs) amplify thrombosis 
via aggregation, coagulation and fibrinolysis processes. Storage-induced PMPs 
express PS, platelet surface proteins (GPIIb/IIIa, GPIb, cluster of differentiation (CD) 
36, CD47) and coagulation factor proteins (tissue factor, activated factor V (FVa)) 
[38, 41]. PMPs initiate platelet plug formation via glycoprotein (GPIb, GPIIb/IIIa) 
adherence to collagen, vWF, fibrinogen and platelets at macrovascular and 
microvascular shear rates [42].  CD36 and CD47 work in concert to mediate platelet 
adherence to inflamed endothelium [43]. PMPs subsequently enhance the propagation 
phase of coagulation via thrombin generation. PMP surface PS assists the assembly of 
prothrombinase complexes that convert prothrombin to thrombin [42].  Additionally, 
PMPs contribute to thrombin-factor XI feedback pathway via membrane-dependent 
activation of factor XI – an important method of thrombin amplification at low tissue 
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factor concentrations [42]. PMP-associated thrombin generation is difficult to curb 
intravascularly as PMP FVa is resistant to activated protein C (APC) inactivation 
[39]. This has been tentatively attributed to poor APC access to FVa secondary to 
FVa binding to multimerin-1 and low-density lipoprotein receptor, along with FVa 
residence in lipid rafts [39]. Further research is required to demonstrate these 
processes.  
 
Pro-inflammatory PSLs 
In vivo, platelets interact with leucocytes via cytokine secretion and CD62P 
attachment to leucocyte surface proteins (Lewis x, sialyl lewis x, P-selectin 
glycoprotein ligand-1, soluble CD40 ligand (sCD40L)) [44].  These interactions are 
essential for immune system activation and modulation at sites of vascular injury and 
pathogen exposure [45]. Defects in these interactions have been attributed to non-
haemolytic transfusion reactions (NHTRs), transfusion-related acute lung injury 
(TRALI) and transfusion-related immunomodulation (TRIM) (Figure 5) [45].  During 
PC preparation and storage, platelet and leucocyte activation lead to the accumulation 
of immunoactive proteins [46]. Early studies in PRP PCs found the accumulation of 
leucocyte-derived cytokines, tumour necrosis factor α (TNF-α), interleukin (IL)-1α, 
IL-6 and IL-8 during 5 day storage [47].  These chemokines were barely detectable in 
BC PCs after 5 day storage – likely secondary to superior leucocyte removal [48].  
Leucoreduction can further decrease leucocyte count to ≤107 leucocytes/PC and 
remove immunoactive proteins based on charge. This leads to low levels of leucocyte-
derived cytokines that remain constant during storage [49]. Negatively charged filters 
are superior at removing positively charged proteins such as complement C4a, PF4, β-
thromboglobulin and IL-8; but are associated with increased neutrophil, monocyte 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 12 
and complement activation [50].  Despite leucoreduction, residual leucocytes retain 
the capacity to produce cytokines de novo during storage [49]. Moreover, 
leucoreduction have limited effect on platelet-derived immune factor and PMP 
accumulation [51, 52]. 
 
Stored PCs accumulate sCD40L which have been associated with immunological 
transfusion reactions such as TRALI and NHTRs via neutrophil activation and 
initiation of B-cell responses [45, 53, 54].  Storage-induced PMPs activate neutrophils 
to mediate leucocyte transmigration and enhance phagocytic activity [55]. In a two-
event model of TRALI, neutrophils stimulated with sCD40L decreased 
lipopolysaccharide (LPS)-stimulated human microvascular endothelial cell viability.  
In this model, LPS simulated the pre-existing condition and sCD40L represented the 
transfusion-related insult [56]. The two-event model of stored PC supernatant-
mediated TRALI is corroborated in an ovine model and prospective patient cohort 
[57, 58].  Additionally, PCs implicated in NHTRs have higher levels of IL-6, IL-8, 
monocyte chemoattractant protein-1 (MCP-1) and sCD40L [59]. PCs with mediator 
levels in the highest quintiles did not induce NHTRs in >93% of patients suggesting 
that patient factors may play a substantial role in the pathogenesis of immunological 
adverse events [59].   
 
Immunomodulatory PSLs 
Storage-induced PMPs can modulate innate (monocyte, macrophage, dendritic cell) 
and adaptive immune cells (regulatory T cells) [41, 60, 61]. Together, these contribute 
to TRIM which has been associated with enhanced survival of renal allografts along 
with increased incidence of post-operative bacterial infections and short-term (up to 
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three-month) mortality [62]. Sadallah et al. observed that PMPs modified macrophage 
and dendritic cell differentiation towards less reactive states [41]. The affected cells 
exhibited reduced pro-inflammatory cytokine secretion (TNF-α, IL-10), impaired 
phagocytic activity and inhibited LPS-induced maturation [41]. Similar to TRALI, 
TRIM may occur via a two-event model whereby, LPS priming is required prior to 
stored PC supernatant exposure to reduce dendritic cell cytokine production [60]. 
More recently, PMPs have been demonstrated to prevent regulatory T cell 
differentiation into a pro-inflammatory state despite anti-CD3/CD28 antibody 
stimulation – suggesting that PMPs may have broader effects on the immune system 
than originally thought [61].  
 
What do PSLs mean for clinical practice? 
Laboratory studies have consistently associated PSLs with haemostatic and immune 
system dysfunction using in vitro and animal models.  These results provide a strong 
benchtop argument that PC preparation and storage are linked with decreased 
transfusion efficacy and safety. However, do these findings translate into adverse 
patient outcomes? The efficacy and safety of stored PC transfusions have been 
predominantly assessed using small observational studies (Supplementary Table 2). 
 
Stored PC efficacy 
PC transfusion efficacy can be assessed using corrected count increment (CCI) along 
with post-transfusion platelet recovery and survival. On meta-analysis of 46 papers, 
Caram-Deelder et al. found that PCs stored for 0-2 days were superior to those stored 
for 5-7 days based on 1-hour and 24-hour CCIs with weighted mean differences of 
2.68 (95% confidence interval (CI): 1.92-3.45) and 1.36 (95% CI: 0.08-2.63), 
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respectively [12]. Post-transfusion recovery and survival of PCs stored for five to 
seven days as a percentage of PCs stored for zero to two days were 80% and 71%, 
respectively [12]. This corroborates in vitro evidence that platelets in PCs undergo 
deteriorations in viability and apoptosis during storage [1]. Furthermore, stored 
platelets are selectively cleared from circulation due to CD62P exposure, GPIbα 
shedding and reduced membrane-associated sialic acid [4, 21, 63].   
 
Importantly, CCIs and platelet survival do not indicate platelet function. Recent 
developments in bedside haemostatic testing have led to the use of viscoelastic tests 
such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM) to 
assess the rate and strength of clot formation. TEG tests of blood collected from 
thrombocytopenic patients 1-hour post fresh BC PC transfusions demonstrated 
superior α angle (rate of clot formation) and K-time (time to fixed level of clot 
firmness) compared to those transfused with stored BC PC [64]. These differences 
were not statistically significant 24 hours post-transfusion suggesting that stored-
induced platelet dysfunction can be recovered after a period of circulation [64]. In 
contrast, TEG of apheresis PCs demonstrate superior α angle, K-time and R-time 
(time to clot initiation) with prolonged storage [65]. This discrepancy could be 
attributed to differing preparation methods (Table 3); however PSLs can also vary 
significantly depending on the surrounding matrix. Early studies found that plasma 
addition to storage media is required to reduce PSLs [9]. Bikker et al. observed that 
post-transfusion platelet function recovery in thrombocytopenic patients can be 
recapitulated by incubating stored PCs with fresh whole blood [66].  
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CCIs, PC survival and recovery only provide cross-sectional data regarding 
transfusion efficacy. Furthermore, these measures require additional blood tests 
and/or the use of radioisotopes which can be expensive and logistically difficult to 
perform. Downstream outcomes such as time to transfusion and bleeding symptoms 
are cumulative indicators of platelet survival and function. A meta-analysis of four 
studies found that transfusion interval was 0.25 days (95% CI: 0 13–0 38) longer after 
≤3 days old PC transfusion compared to ≥4 days old PC transfusion [67]. In blood 
stem cell transplant patients, reducing non-leucoreduced PC shelf life from five days 
to four days was associated with reduced bleeding symptoms such as epistaxis, 
haematuria and bleeding at multiple sites [68]. Transfusions of fresh PCs were linked 
to prolonged transfusion interval in acute myeloid leukaemia and intensive 
chemotherapy patients [69, 70]. Lastly, in multiple haematological malignancy 
cohorts, the requirement for a repeat PC transfusion within 24 hours increased with 
PC storage duration [71, 72]. Conversely, four studies found that platelet storage 
duration did not predict transfusion interval or time to first clinically significant bleed 
in haematology patients [73-76].  
 
Stored PC safety 
Studies of stored P  transfusion safety vary in reported outcomes and findings.  A 
recent meta-analysis of seven studies associated increased PC storage duration with 
increased risks of immune-mediated transfusion reactions [67]. In 381 trauma 
patients, stored PC transfusions were associated with increased rates of sepsis but not 
ARDS, mortality, renal failure nor liver failure [77]. PC storage duration was not 
associated with 30-day mortality, prolonged hospital length of stay (>10 days), 
infectious complications or long-term survival (>5 years) in aortocoronary bypass 
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surgery patients [78].  There is insufficient evidence to discern the effect of PSLs on 
transfusion safety due to equivocal data in the setting of patient sample and outcome 
heterogeneity.  
 
Most studies investigating the clinical effects of PC storage duration have utilised 
small cohorts, observational protocols and subset analyses which are vulnerable to 
bias and confounding factors. Large randomised controlled trials (RCTs) similar to 
the Age of Blood Evaluation (ABLE) and Standard Issue Transfusion versus Fresher 
Red Blood Cell Use in Intensive Care (TRANSFUSE) studies should be conducted to 
robustly assess the risks of stored PC transfusions [79].  This is particularly important 
considering the widespread implications of storage-induced adverse outcomes for 
clinical practice and blood bank management. For example, if fresh PCs could 
prolong transfusion interval in thrombocytopenic patients, its selective use for 
bleeding prophylaxis could significantly reduce exposure to alloimmunisation and 
standard transfusion risks.  
 
PSL research: a moving target 
Correlating clinical and laboratory findings 
Platelets undergo activation and metabolic alterations during PC preparation and 
storage in vitro.  However, in vitro functional defects correlate poorly with clinical 
observations. For example, platelet activation in transfused PCs was not correlated to 
post-operative chest drain fluid volume, a surrogate marker for blood loss after 
coronary bypass surgery [80]. Storage-induced defects in platelet aggregation in vitro 
can be overcome by using multiple agonists, which better approximate the in vivo 
environment [81].  It follows that PSLs interact with endogenous cells and mediators 
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in a complex manner to affect multiple targets of the haemostatic cascade.  While 
simple in vitro models have advanced knowledge of individual PSL components, 
complex models that incorporate dynamic factors are required to understand how 
PSLs interact with recipient conditions. Future studies could test PSLs using vascular 
(under flow conditions) and transfusion (mixed with whole blood) models that better 
approximate the in vivo environment.   
 
Complex models and in vivo studies are complicated by numerous sources of 
variability. For example, leucocyte concentration and platelet activation can vary 
between donors (Supplementary Table 3) [21, 50, 82-84].  Although there has been 
some work investigating the merits of donor selection to improve PC quality and 
safety, currently there is insufficient evidence to select donors based on these traits 
[82]. Considering that the myriad of interactions between PC and recipient factors are 
poorly understood, in vivo studies are vulnerable to unchecked confounders which 
could mask small positive effects that are limited to selective patient populations. 
Similarly, meta-analyses are difficult to interpret due to jurisdictional and time-
associated variations in donor characteristics, PC preparation methods and shelf life.  
This could be addressed by combining patient level data from studies with the same 
storage guidelines. However, the merits of intensive clinical data mining to identify 
such a small selective adverse effect margin has to be questioned in the context of an 
already short PC shelf life of 5-7 days with little room to move should an adverse 
effect be found.  This is particularly significant considering that median PC expiry 
rates decrease from 6.8% to 3.1% when moving from 5 to 7 day jurisdictions [85].  
Instead, research should focus on the development of technologies that abrogate PSLs 
and prolong shelf life.   
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Improving room temperature platelet concentrates 
PSLs secondary to platelet metabolism and activation at room temperature storage can 
be improved via advances in bag materials and storage media (Figure 3). Bag 
materials such as 1,2-cyclohexane-dicarboxylic acid diisonoylester (DINCH)-PVC 
are purported to be less toxic than current BTHC- or TEHTM- PVC bags, owing to 
decreased phthalate contamination [85, 86]. Furthermore, PCs stored in DINCH-PVC 
for 7 days have lower glycolytic activity and platelet activation compared to BTHC-
PVC [86]. Transfusion studies of DINCH-PVC stored PCs are required prior to their 
implementation in blood banks. Several investigators have used the addition of small 
molecules to combat specific PSL mechanisms (Supplementary Table 4). L-carnitine 
facilitates transport of long chain fatty acids into the mitochondrial matrix to redirect 
ATP generation towards β-oxidation thereby, reducing glucose consumption and 
lactate accumulation in PRP PCs [87]. Mitogen activated protein kinase inhibitors 
such as VX-702, have been added to PAS to prevent GPIb shedding and oxidative 
damage [88]. VX-702 treated PCs exhibit improved glucose availability, pH, 
morphology score, HSR, reactive oxygen levels and platelet activation [88].   
 
Cryopreserved platelet concentrates 
Decreasing storage temperature can lengthen PC shelf life by reducing metabolism-
related PSLs and bacterial contamination. The most commonly used PC 
cryopreservation protocol involve adding dimethyl sulfoxide (DMSO) to room 
temperature PCs (final concentration of 4-6%), followed by centrifugation to remove 
DMSO prior to storage at -80°C for 2-4 years [89].  Cryopreserved PCs are placed in 
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a water bath for rapid thawing and then reconstituted in: plasma, PAS or a mixture of 
both similar to room temperature PCs [89]. These PCs have mean survival of 7.0  
days and 24 hour recovery rates of 41.6%, which satisfies the USA Food and Drug 
Administration (FDA) requirements for survival but not 24 hour recovery [90]. 
Cryopreserved PCs demonstrate increased activation via P-selectin expression along 
with decreased aggregation responses to ADP and collagen [91].  Despite decreased 
in vitro platelet aggregation efficacy, cardiopulmonary bypass patients receiving 
cryopreserved PCs experienced decreased blood loss and post-operative blood 
production requirements compared to those receiving room temperature PCs [92]. 
This is supported by anecdotal evidence from Dutch military hospitals whereby, 
cryopreserved PCs stopped severe bleeding without increasing platelet count, 
suggesting that soluble components such as microparticles may contribute to the 
procoagulant effects of cryopreserved PCs [93]. To date, cryopreserved PCs are 
approved for general use in France and only for military operations in the Netherlands 
and Germany [89].  The CLIP trial (ACTRN12612001261808) is a multi-centre 
blinded RCT currently underway to compare the efficacy of cryopreserved PCs versus 
standard PCs for the management of post-surgical bleeding in civilian populations 
[94]. Similarly, large RCTs are required to determine the efficacy of prophylactic 
cryopreserved PC transfusion. Even if the efficacy of cryopreserved PCs is 
established in civilian settings, the extra time and equipment costs associated with PC 
cryopreservation and thawing remain a major barrier for widespread use.  
Additionally, standardisation of cryopreserved PC preparation and thawing are 
required prior to implementation.  
 
Cold stored platelet concentrates 
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Alternatively, cold stored (at 2-6°C) PCs are easier to prepare and store.  In 2015, the 
FDA approved cold stored PCs for resuscitation of bleeding patients. Cold stored PCs 
have decreased bacterial contamination risks and improved haemostasis compared to 
room temperature PCs [95, 96].  Compared to room temperature PCs, cold stored PC 
transfusions led to superior platelet function in paediatric cardiac surgery patients and 
shorter bleeding times in adults taking aspirin[97, 98]. A clinical trial is currently 
underway at Haukeland University Hospital, Norway to investigate the efficacy of 
cold stored PCs in cardiothoracic surgery patients (NCT02495506). Notably, cold 
stored PCs exhibit decreased survival and recovery compared to room temperature 
PCs making them less suitable for bleeding prophylaxis in thrombocytopenic patients 
[99].  
  
Platelet surface glycoprotein alterations and cold-induced platelet activation are 
associated with reduced post-transfusion platelet survival (Figure 6). During cold-
storage, platelets undergo Rho GTPase-induced clustering of β-N-acetylglucosamine 
on α subunits of GPIb [100, 101]. These microdomains are recognised by complement 
receptors on macrophages leading to platelet phagocytosis and clearance [100]. 
Enzymatic galactosylation prevented complement receptor recognition of β-N-
acetylglucosamine residues in vitro [102]. However, enzymatic galactosylation did 
not improve platelet survival in vivo, suggesting that multiple mechanisms may be 
involved in cold-stored platelet clearance [99]. RhoA inhibitors addition to storage 
media work upstream to prevent glycoprotein clustering during cold storage. Such 
PCs led to similar collagen-induced platelet shape change and aggregation, and 
bleeding time correction in aspirated mice and Rhesus monkeys compared to room 
temperature stored platelet concentrates [103].   
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Cold-induced platelet activation causes calcium influx leading to calcium-dependent 
gelosin activation, phosphoinositide-mediated actin polymerisation and ultimately, 
loss of platelet discoid morphology [1]. Enhanced intracellular calcium also facilitates 
α-granule and lysosomal content release; thereby, amplifying platelet activation 
during cold storage [101]. Attempts have been made to curtail cold-induced platelet 
activation via metabolic suppression with glucose-free media and antimycin A 
(mitochrondrial inhibitor) [101]. Double blockade was required to decrease cold-
induced platelet activation and macrophage binding [104]. Notably, antimycin A is 
highly toxic at its effective concentration and inappropriate for clinical use. Storage 
media with second messenger effectors (ThromboSol: LifeCell Corporation) such as 
amiloride, adenosine, sodium nitroprusside, dipyridamole, ticlopidine and quinacrine 
was formulated to prevent cold-induced platelet activation [105]. Amiloride inhibited 
sodium/hydrogen ion pump, adenosine inhibited intracellular cyclic adenosine 
monophosphate and sodium nitroprusside enhanced nitric oxide release [106]. PCs 
cold stored in ThromboSol showed reduced platelet activation and improved in vitro 
function compared to untreated PCs however, its impact on platelet survival in vivo 
remains to be seen [106, 107]. More recently, resolvins, a class of specialised 
proresolving mediators, have been proposed as a storage media additive to reduce 
cold-induced platelet activation [108]. Further investigations are required to link 
reduced platelet activation to improved post-transfusion platelet survival.  
 
It follows that PSLs are storage method dependent – necessitating the shift towards 
investigating cold stored PSLs. Understanding PSLs as a function of storage method 
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are necessary to facilitate cold storage, which can prolong shelf life and simplify PC 
storage protocols.  
 
Turning the tables on microparticles 
For example, while PSLs such as PMPs can lead to enhanced thrombogenicity and 
immunoactivity, microparticles can also transfer peptides, proteins, lipids, microRNA, 
mRNA, and DNA from one cell to another to alter recipient cell function [109].  
Recent advances in microfluidics have enabled the development of liposomes less 
than 30µm loaded with desired transmembrane and cytoskeletal proteins [110]. In the 
future, these bioengineered microparticles could be incorporated in storage media to 
prevent or replenish storage-related changes in platelet membrane markers such as 
CD62P, PAR1, PAR4 and GPIbα. Furthermore, the divergence between microparticle 
and parent surface markers suggest that microparticle formation remove specific 
proteins from the cell membrane [109]. Selective vesiculation may be applied to 
remove deleterious markers from stored platelets. In this way, identification of PSLs 
are critical for devising methods to abrogate PSLs and prolong PC shelf life.  
 
Final remarks 
PSLs develop during PC preparation and storage.  Mechanical and biochemical forces 
during PC preparation induce platelet activation which persist throughout storage 
duration. Changes in platelet surface receptors and PMP elaboration impair platelet 
aggregation. Soluble factors and PMPs accumulated during storage interfere with the 
delicate balance of inflammatory and immunomodulatory factors. Clinically, PSLs 
have been associated with reduced CCI and platelet survival but not adverse 
transfusion events. Current developments to reduce room temperature PSLs have 
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focused on reducing platelet glycolysis and activation, via bag material and storage 
media changes. Cryopreservation and cold storage offer the potential for prolonged 
storage, reduced bacterial proliferation and improved haemostasis in trauma 
populations. Further research is required to define storage-specific PSLs so that the 
mechanisms underlying cold-induced platelet activation and reduced platelet survival 
can be addressed.   
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Table 1: Platelet granule contents and function in haemostasis 
Granule Class Components Function 
α Large adhesive 
proteins 
vWF 
Thrombospondin-1 
Vitronectin 
Fibronectin 
Platelet aggregation 
Mitogenic factors VEGF  
TGF-β 
PDGF  
Wound repair 
Coagulation factors Factors V, VII, XII, XII Coagulation 
Protease inhibitors Protein C 
PAI-1 
TFPI 
Anticoagulation 
Soluble immune 
factors 
PF4 
RANTES 
β-thromboglobulin/NAP-2 
sCD40L 
Inflammation 
Dense Dense granule 
contents 
ADP, ATP 
Serotonin 
Calcium pyrophosphate 
Platelet activation/aggregation 
Platelet activation/aggregation 
Coagulation 
Abbreviations: ADP=adenosine diphosphate, ATP=adenosine triphosphate, NAP-2=neutrophil 
activating peptide-2, PAI-1=plasminogen activator inhibitor, PDGF=platelet derived growth factor, 
PF4=platelet factor 4, RANTES=regulated on activation, normal T cell expressed and secreted, 
sCD40L=soluble CD40 ligand, TFPI=tissue factor pathway inhibitor, TGF-β=transforming growth 
factor β, VEGF=vascular endothelial growth factor, vWF=von Willebrand factor 
 
Table 2: Indications for platelet transfusion 
Prophylactic Treatment 
 Hypoproliferative thrombocytopenia 
 Increased risk of bleeding (platelets <5,000/µl) 
 Bone marrow failure 
o Platelets <10,000/µl if no risk factors  
o Platelets <20,000/µl if fever, on 
antibiotics, evidence of systemic 
haemostatic failure  
 Surgery/invasive procedure  
o Aim to keep platelets >50,000/µl 
 High risk of bleeding  
o Aim to keep platelets >100,000/µl 
 Bleeding where thrombocytopenia is major 
contributing factor 
 Massive haemorrhage/transfusion   
o As part of massive transfusion protocol 
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Table 3: Differences in PSL by PC preparation method 
PSL AP PCs BC PCs PRP PCs 
MPV[19, 111] ↓ over 5 days No change No change (PRP PC< 
BC PC) 
PRW[19] ↓ over 5 days No change - 
% depolarized 
MMP[19] 
No change ↑ over 5 days - 
GPIbα[19, 112] ↓ over 7 days (AP PC 
<BC PC) 
↓ over 7 days ↓ over 7 days (PRP PC 
< AP PC) 
CD47[19] No change (AP PC 
>BC-PC) 
No change - 
GPIIIa[19] No change (AP PC 
>BC-PC) 
No change - 
Platelet 
activation[112, 113] 
↑ over 5 days (AP PC 
>BC-PC) 
↑ over 5 days ↑ over 5 days (PRP PC 
>AP-PC) 
Metabolism[113, 
114] 
↑ Glucose consumption + ↑ lactate secretion (AP PC > BC PC = PRP PC) 
Abbreviations: AP PC=apheresis platelet concentrates; BC PC=buffy coat platelet concentrates; 
MMP=mitochondrial membrane potential; MPV=mean platelet volume; PRP PC = platelet rich plasma 
platelet concentrates, PRW=platelet redistribution width 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 41 
Figure 1 – Role of platelets in thrombus formation.  Platelets activate on contact with 
subendothelial proteins (collagen, von Willebrand’s factor) to express P-selectin and release 
microparticles, α granules and dense granules.  Activated platelets aggregate in response to 
collagen, epinephrine, ADP, thrombin, fibrinogen, von Willebrand’s factor, platelet 
activating factor and thrombin receptor-activating protein-6. Microparticles, tissue factor and 
activated factor V released by platelets enhance thrombin generation to provide positive 
feedback for thrombus generation.  
 
Figure 2 – Platelet concentrate preparation methods. Platelet rich plasma (PRP) PCs 
utilises soft centrifugation to first separate platelets and plasma from red and white blood 
cells. Hard centrifugation subsequently pellets platelets.  In contrast, buffy coat (BC) PCs are 
produced via an initial hard centrifugation to concentrate platelets into the BC, which 
undergoes soft centrifugation to remove remaining red blood cells.  Platelets from four to six 
donors are pooled to produce a therapeutic dose of PRP or BC PCs (>3x10
11
 platelets).  For 
apheresis PCs, whole blood is collected into an automated cell separator which centrifuges 
whole blood and collects platelets, while returning other components to the donor. As 3.5L of 
donor blood can be processed per collection, each apheresis PC unit is sourced from a single 
donor.  Platelets from BC and apheresis PCs are resuspended in a mixture of platelet additive 
solution and plasma, whereas, PRP BCs remain suspended in plasma only.  
 
Figure 3 – Room-temperature (RT) PSLs and management strategies (blue). 
ADP=adenosine diphosphate, DINCH-PVC=1,2-cyclohexane-dicarboxylic acid 
diisonoylester-polyvinyl chloride, HSR=hypotonic shock response, LDH=lactic 
dehydrogenase, NO=nitric oxide, NAAGA=N-acetylaspartylglutamic acid, PAR=protease-
activated receptors, PC=platelet concentrate, PMP=platelet microparticles, 
TCA=tricarboxylic acid  
 
Figure 4 – Platelet metabolism and associated PSLs.  Glucose enters from the surrounding 
environment and can undergo glycolysis (non-oxidative) in the cytoplasm to produce 
pyruvate and a small amount of ATP. Pyruvate participates in oxidative phosphorylation in 
the mitochondrial matrix via the tricarboxylic acid cycle.  The citric acid cycle produces 
electron donors (NADH + FADH2) which are fed into the electron transport chain for bulk 
ATP production.  Proteins at the mitochondrial membrane pump hydrogen into the 
intermembrane space to generate the mitochondrial membrane potential.  The mitochondrial 
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membrane potential drives the ATP synthase to produce ATP which is required for platelet 
function.  During PC storage, glycolysis is upregulated while mitochondrial function is 
suppressed. This leads to increased glucose consumption and lactic acid secretion along with, 
decreased ATP production. Ultimately, these changes are linked to storage media 
acidification, decreased platelet survival and aggregation.  
 
Figure 5 – Immune system effects of PSLs. Platelets and contaminating leukocytes in 
stored platelet concentrates (PCs) mediate immune system dysfunction via cytokines and 
platelet microparticles (PMPs). These constituents combine to cause non-haemolytic 
transfusion reactions, transfusion-related lung injury and transfusion-related 
immunomodulation. The latter two reactions require a “1st hit” such as endotoxaemia which 
has been simulated by lipopolysaccharide (LPS) addition in vitro.  
 
Figure 6 – Cold storage PSLs and management strategies (blue). Ca2+=calcium. 
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Highlights 
 Platelet storage lesions (PSLs) form during platelet concentrate preparation and storage  
 PSLs include storage media changes (such as nutrient depletion and waste accumulation), 
platelet marker alterations and microparticle formation 
 PSLs affect platelet activation, aggregation and immune function 
 PSLs lead to decreased transfusion efficacy but do not affect transfusion safety 
 Future research involve vascular flow models, storage media and temperature optimisation 
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